Treatment and Access: A Critical Gap in Care

Chagas disease is treatable, especially when diagnosed early. Antiparasitic medications such as benznidazole and nifurtimox are effective in eliminating or reducing the parasite load, particularly in the acute and early chronic phases.

However, access to diagnosis and treatment remains a major challenge. In Latin America, barriers include limited healthcare infrastructure, lack of awareness, and socioeconomic factors. In the United States, challenges include underdiagnosis, limited provider familiarity, and gaps in routine screening for at-risk populations.

Even though treatments are available through programs coordinated with health authorities such as the Centers for Disease Control and Prevention (CDC), many patients remain untreated due to lack of awareness or access.

Closing this gap requires:

• Expanding screening programs, especially for pregnant women and blood donors

• Increasing provider education and clinical awareness

• Improving access to affordable diagnostic testing

• Strengthening partnerships between nonprofit organizations, healthcare systems, and public health agencies

Early treatment can significantly reduce the risk of long-term complications, making access to care a life-saving priority.